Post-earnings recap
Reported
Mon, Nov 11, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Castle Biosciences reported an EPS of $0.05, but without revenue figures or guidance, investors may be uncertain about the company's performance. The stock reacted negatively, declining by 1.22%, reflecting a lack of clarity in the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.05 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.